Branded formulations drive Eris Lifesciences' Q2 PAT up by 10% to Rs 118 cr

Revenue from operations grow 9% YoY to Rs 360 crore

With its branded formulations business outperforming the market growth by nearly 50 per cent since pre-pandemic times, Eris Lifesciences Ltd has posted a 10 per cent growth in its profit after tax (PAT) at Rs 118.3 crore for the second quarter ended September 30, 2021.

The pharmaceutical major's revenue from operations also grew by nine per cent to Rs 359.67 crore on a year-on-year (YoY) basis in Q2 of FY 2021-22, up from Rs 329.99 crore in Q2  of FY 2020-21.

According to Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd., the company's branded formulations business has outperformed the market